InterCure Ltd.
NASDAQ:INCRDrug Manufacturers - Specialty & Generic
-$0.04 today
- Market cap
- $51.63M
- Beta
- 0.57
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.04M
INCR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
InterCure Ltd.NASDAQ: INCR
Selling, General & Admin · Q2 FY2025 · quarter ended Jun 2025
Selling, general & admin dips below year-ago levels
Q2 FY2025 selling, general & admin of ₪20.65M fell 11.2% year over year, behind the +12.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.
Context
- Selling, general & admin amounted to 29.8% of revenue in FY2025, down 5.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether next quarter's selling, general & admin reaches the consensus estimate of ₪18.57M, a -41.6% change from the same quarter last year.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2025
- ₪20.65M+0.0% QoQ
- Last fiscal yearDec 2025
- ₪80.41M-5.0% YoY
- LTMJun 2025
- ₪104.96M+12.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -11.2% | -41.6% | -30.4 pp |
| 1 year | -5.0% | — | — |
| 3-year CAGR | -6.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
ILS · from the income statement
- Latest · FY2025
- 80.41M ILS
- Year-over-year change
- -5.0%
- 4-year CAGR
- +10.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.41M | -5.0% |
| FY2024 | 2024-12-31 | 84.63M | -1.9% |
| FY2023 | 2023-12-31 | 86.24M | -11.4% |
| FY2022 | 2022-12-31 | 97.32M | +82.0% |
| FY2021 | 2021-12-31 | 53.46M | — |
Selling, General & Admin vs competitors
How INCR compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.9% is the 3rd highest of 9, against a peer median of -9.2%.
- Selling, general & admin amounts to 43.2% of revenue for INCR, versus a peer median of 100.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $120.99M USD | -30.8% | -16.8% | 51.0% | |
| LTM Jun 2025 | ₪104.96M ILS | +12.9% | -6.2% | 43.2% | |
| LTM Mar 2026 | $86.8M USD | -8.8% | -5.3% | 131.2% | |
| LTM Mar 2026 | $66.32M USD | -15.5% | +12.7% | 64.9% | |
| LTM Mar 2026 | $21.4M USD | +37.8% | +45.9% | — | |
| LTM Mar 2026 | CA$20.29M CAD | -9.6% | +7.3% | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$18.43M CAD | +3.9% | +1.8% | 100.4% |
| LTM Mar 2026 | $17.75M USD | +13.9% | — | 451.2% | |
| LTM Mar 2026 | $16.17M USD | -36.6% | -2.6% | — | |
| Peer median (excluding INCR) | — | -9.2% | +1.8% | 100.4% | |
Competitors are the stored peer set for INCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 219.68M | 388.68M | 355.55M | 238.85M | 270.2M |
| Cost of Revenue | 128.55M | 233.6M | 250.46M | 208.61M | 237.02M |
| Gross Profit | 91.13M | 155.08M | 105.1M | 30.23M | 33.18M |
| Gross Margin | 41.5% | 39.9% | 29.6% | 12.7% | 12.3% |
| Research & Development | 1.24M | 632K | 388K | 414K | 390K |
| Selling, General & Admin | 53.46M | 97.32M | 86.24M | 84.63M | 80.41M |
| Operating Expenses | 62.95M | 104.46M | 146.66M | 97.44M | 26.45M |
| Depreciation & Amortization | 7.39M | 11.7M | 13.17M | 15.37M | 17.15M |
| EBITDA | 31.17M | 70.23M | (23.9M) | (51.31M) | (7.29M) |
| EBITDA Margin | 14.2% | 18.1% | -6.7% | -21.5% | -2.7% |
| Operating Income | 28.19M | 50.63M | (41.57M) | (67.21M) | 6.73M |
| Operating Margin | 12.8% | 13.0% | -11.7% | -28.1% | 2.5% |
| Interest Income | 130K | 844K | 4.55M | 2.7M | 1.56M |
| Interest Expense | 5.05M | 14.69M | 24.22M | 20.65M | 19.66M |
| Other Income / Expenses | (9.45M) | (6.79M) | (19.72M) | (20.12M) | (50.84M) |
| Income Before Tax | 18.74M | 43.84M | (61.29M) | (87.32M) | (44.1M) |
| Pre-Tax Margin | 8.5% | 11.3% | -17.2% | -36.6% | -16.3% |
| Income Tax Expense | 11.44M | 93K | 2.25M | (14.53M) | (7.32M) |
| Net Income | 4.69M | 44.82M | (61.96M) | (67.8M) | (35.71M) |
| Net Margin | 2.1% | 11.5% | -17.4% | -28.4% | -13.2% |
| EPS (Basic) | 0.12 | 0.99 | (1.36) | (1.42) | (0.63) |
| EPS (Diluted) | 0.11 | 0.99 | (1.36) | (1.42) | (0.63) |
| Weighted Avg Shares | 38.49M | 45.35M | 45.56M | 47.77M | 56.8M |
| Weighted Avg Shares (Diluted) | 40.84M | 45.35M | 45.57M | 47.77M | 56.8M |
InterCure Ltd.
NASDAQ:INCR
Intrinsic Alpha fair value
Locked
Current Price
$3.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.